Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
DOD Toxic Exposures, Clinical Trial Award
The TERP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures.
To meet the intent of the award mechanism, applications must address at least one of the FY23 TERP Programmatic Goals and at least one of the FY23 TERP Topic Areas.Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.
It is anticipated that outcomes from studies funded by this award will follow a clinical development plan that advances the research to U. S. Food and Drug Administration (FDA) device or drug approval and/or establishment of clinical practice guidelines, as applicable.Applications to the TERP CTA mechanism must support a clinical trial and may not be used for animal or other preclinical research studies.
The application will be withdrawn if the proposed research is not a clinical trial.
To meet the intent of the award mechanism, applications must address at least one of the FY23 TERP Programmatic Goals and at least one of the FY23 TERP Topic Areas.Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.
It is anticipated that outcomes from studies funded by this award will follow a clinical development plan that advances the research to U. S. Food and Drug Administration (FDA) device or drug approval and/or establishment of clinical practice guidelines, as applicable.Applications to the TERP CTA mechanism must support a clinical trial and may not be used for animal or other preclinical research studies.
The application will be withdrawn if the proposed research is not a clinical trial.
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
Program Announcement
Additional Information of Eligibility:
Applicants are limited to for-profit (commercial) organizations, nonprofit organizations, faith-based and community organizations, institutions of higher learning, and consortia with demonstrated organizational and community-based experience working with American Indian and Alaska Native communities, including tribal for-profit (commercial) and nonprofit organizations, tribal colleges and universities, and tribal consortia.
However, consistent with OJP fiscal requirements, for-profit organizations are not allowed to make a profit as a result of this award or charge a management fee for the performance of this award.
Full Opportunity Web Address:
http://www.bjs.gov/content/pub/pdf/leaic_sol.pdf
Contact:
Agency Email Description:
CDMRP Help Desk
Agency Email:
Date Posted:
2023-07-07
Application Due Date:
Archive Date:
2023-11-03
Social Entrepreneurship
Spotlight
When it Comes to Social Enterprises, Failure is the Best Platform for Innovation
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.
Learn How to Identify and Avoid Grant Scams
